Lord’s Mark Industries outlines a strategy to expand its presence across global healthcare, advanced diagnostics, and oncology. The company also sets a financial target of Rs 1,550 crore in revenue for FY2027, according to reports.
NDTV adds that the company’s progress includes innovation work on its OneDNA genomic testing platform. It says patient trials for OneDNA have been completed following approval by India’s ICMR (Indian Council of Medical Research). The Times of India article focuses more on the overall expansion direction and the company’s revenue goal, while NDTV highlights the status of the OneDNA platform’s trials and regulatory step.
Taken together, the reporting presents a picture of an expansion roadmap supported by work in genomic testing and a broader push into diagnostics and oncology, with timelines and targets referenced around FY2027.
